Advertisement

HIV-Infektion im Kindesalter – Update

  • Uwe WintergerstEmail author
  • Ulrich Baumann
  • Ulrich v. Both
  • Bernd Buchholz
  • Cornelia Feiterna-Sperling
  • Elisabeth Förster-Waldl
  • Robin Kobbe
  • Christoph Königs
  • Elke Maritz
  • Jennifer Neubert
  • Tim Niehues
  • Gundula Notheis
  • Paolo Paioni
Originalien

Zusammenfassung

Das Update ist eine Zusammenfassung des im neuen Handbuch (7. Auflage) erscheinenden Kapitels über Infektion mit Humanem Immundefizienz-Virus (HIV) der Deutschen Gesellschaft für pädiatrische Infektiologie sowie der derzeit in Überarbeitung befindlichen Leitlinie HIV-Infektion der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AMWF) im Kindesalter. Es werden die neuesten Empfehlungen hinsichtlich Therapie der pädiatrischen HIV-Infektion, supportiven Therapien und Prävention der vertikalen HIV-Transmission und Postexpositionsprophylaxe nach akzidenteller HIV-Exposition vorgestellt.

Schlüsselwörter

HIV Kinder Jugendliche Antiretrovirale Therapie Prophylaxe der vertikalen HIV-Infektion Prophylaxe nach Stichverletzungen 

HIV Infection in Childhood: Update

Abstract

This update is a summary of the chapter on infection with the human immunodeficiency virus (HIV) in childhood published in the new Handbook of the German Society on Pediatric Infectious Diseases (7th edition) and the revised edition of the Association of Scientific Medical Societies in Germany (AWMF) guidelines. The latest recommendations relating to treatments for pediatric HIV infection, supportive therapies, and the prevention of vertical HIV transmission in addition to post-exposure prophylaxis after accidental HIV exposure will be presented.

Keywords

HIV Children Youngsters Antiretroviral Therapy Prophylaxis of vertical HIV transmission Prophylaxis after stab injury 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

U. Wintergerst, U. Baumann, U. v. Both, B. Buchholz, C. Feiterna-Sperling, E. Förster-Waldl, R. Kobbe, C. Königs, E. Maritz, J. Neubert, T. Niehues, G. Notheis und P. Paioni geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD; INSIGHT START Study Group (2015) Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 373(9):795–807CrossRefGoogle Scholar
  2. 2.
    Bamford A, Turkova A, Lyall H, Foster C, Klein N, Bastiaans D, Burger D, Bernadi S, Butler K, Chiappini E, Clayden P, Della Negra M, Giacomet V, Giaquinto C, Gibb D, Galli L, Hainaut M, Koros M, Marques L, Nastouli E, Niehues T, Noguera-Julian A, Rojo P, Rudin C, Scherpbier HJ, Tudor-Williams G, Welch SB; PENTA Steering Committee (2018) Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life. HIV Med 19(1):e1–e42.  https://doi.org/10.1111/hiv.12217 CrossRefPubMedGoogle Scholar
  3. 3.
    Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA et al (2008) Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 359(21):2233–2244CrossRefGoogle Scholar
  4. 4.
    Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, Green H, Galli L, Ramos JT, Giaquinto C, Warszawski J, Levy J; European Infant Collaboration group (2009) Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 23(5):597–604.  https://doi.org/10.1097/QAD.0b013e328326ca37 CrossRefGoogle Scholar
  5. 5.
    Puthanakit T, Ananworanich J, Vonthanak S et al (2013) Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study. Pediatr Infect Dis J 32(5):501–508CrossRefGoogle Scholar
  6. 6.
    Schomaker M, Leroy V, Wolfs T, et al (2017) Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe. Int J Epidemiol 46(2):453–465.  https://doi.org/10.1093/ije/dyw097 CrossRefPubMedGoogle Scholar
  7. 7.
    Szubert AJ, Musiime V, Bwakura-Dangarembizi M, Nahirya-Ntege P, Kekitiinwa A, Gibb DM, Nathoo K, Prendergast AJ, Walker AS; ARROW Trial Team (2015) Pubertal development in HIV-infected African children on first-line antiretroviral therapy. AIDS 29(5):609–618.  https://doi.org/10.1097/QAD.0000000000000590 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Shearer WT1, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, Rich K, Handelsman E, Diaz C, Pagano M, Smeriglio V, Kalish LA (1997). Iral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 336(19):1337–1342CrossRefGoogle Scholar
  9. 9.
    Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358(6):568–579CrossRefGoogle Scholar
  10. 10.
    Green H, Gibb DM, Walker AS, Pillay D, Butler K, Candeias F, Castelli-Gattinara G, Compagnucci A, Della Negra M, de Rossi A, Feiterna-Sperling C, Giaquinto C, Harper L, Levy J, Saidi Y, Wintergerst U (2007) Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. Paediatric European Network for the Treatment of AIDS (PENTA). AIDS 21(8):947–955CrossRefGoogle Scholar
  11. 11.
    Cotton MF, Holgate S, Nelson A, Rabie H, Wedderburn C, Mirochnick M (2015) The last and first frontier-emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. J Int AIDS Soc 18(Suppl 6):20271PubMedPubMedCentralGoogle Scholar
  12. 12.
    de Waal R, Kroon SM, Holgate SL et al (2014) Nevirapine concentrations in preterm and low birth weight HIV-exposed infants: implications for dosing recommendations. Pediatr Infect Dis J 33(12):1231–1233. http://www.ncbi.nlm.nih.gov/pubmed/24945881 CrossRefGoogle Scholar
  13. 13.
    Capparelli EV, Rossi S et al (2017) Nevirapine (NVP) concentrations in HIV-infected newborns receiving therapeutic dosing. Abstract 815, CROI, Seattle, WAGoogle Scholar
  14. 14.
    Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, Bwakura-Dangarembizi M, Chi BH, Musoke P, Kamthunzi P, Schimana W, Purdue L, Eshleman SH, Abrams EJ, Millar L, Petzold E, Mofenson LM, Jean-Philippe P, Violari A (2010) Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 363(16):1510–1520CrossRefGoogle Scholar
  15. 15.
    Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens et al (2007) Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356(2):135–147CrossRefGoogle Scholar
  16. 16.
    Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, Morris L, Kuhn L (2011) HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS 25(12):1461–1469CrossRefGoogle Scholar
  17. 17.
    Saez-Llorens X, Violari A, Deetz CO, Rode RA, Gomez P, Handelsman E et al (2003) Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 22:216–224PubMedGoogle Scholar
  18. 18.
    Clarke DF, Wong RJ, Wenning L, Stevenson DK, Mirochnick M (2013) Raltegravir in vitro effect on bilirubin binding. Pediatr Infect Dis J 32(9):978–980CrossRefGoogle Scholar
  19. 19.
    Wong E, Trustman N, Yalong A (2016) HIV pharmacotherapy: A review of integrase inhibitors. JAAPA 29(2):36–40.  https://doi.org/10.1097/01.JAA.0000475465.07971.19 CrossRefPubMedGoogle Scholar
  20. 20.
    Kiser JJ, Rutstein RM, Samson P et al (2011) Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. AIDS 25(12):1489–1496CrossRefGoogle Scholar
  21. 21.
    Rutstein RM, Samson P, Fenton T, Fletcher CV, Kiser JJ, Mofenson LM et al (2015) with the PACTG 1020A Study Team. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: The Pediatric AIDS Clinical Trials Group Protocol 1020A. Pediatr Infect Dis J 34:162–167CrossRefGoogle Scholar
  22. 22.
    Blanche S, Bologna R, Cahn P, Rugina S, Flynn P, Fortuny C, Vis P, Sekar V, van Baelen B, Dierynck I, Spinosa-Guzman S (2009) Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS 23(15):2005–2013.  https://doi.org/10.1097/QAD.0b013e328330abaa CrossRefPubMedGoogle Scholar
  23. 23.
    Viani RM, Alvero C, Fenton T, Acosta EP, Hazra R, Townley E, Steimers D, Min S, Wiznia A; P1093 Study Team (2015) Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093. Pediatr Infect Dis J 34(11):1207–1213.  https://doi.org/10.1097/INF.0000000000000848 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Wiznia A Alvero C, Fenton T, George K, Townley E, Hazra R, Graham B, Buchanan A, Vavro C, Viani R, for the IMPAACT P1093 (2016) IMPAACT 1093: Dolutegravir in 6- to 12-Year-Old HIV-Infected Children: 48-Week Results. 23. Conference on Retrovirusus and opportunistic Infections, Abstract 816, Boston, MAGoogle Scholar
  25. 25.
    Gaur AH, Kizito H, Prasitsueubsai W, Rakhmanina N, Rassool M, Chakraborty R, Batra J, Kosalaraksa P, Luesomboon W, Porter D, Shao Y, Myers M, Ting L, SenGupta D, Quirk E, Rhee MS (2016) Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Lancet HIV 3(12):e561–e568.  https://doi.org/10.1016/S2352-3018(16)30121-7 CrossRefGoogle Scholar
  26. 26.
    Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M; EMERALD study group (2018) Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV 5(1):e23–e34.  https://doi.org/10.1016/S2352-3018(17)30179-0 CrossRefGoogle Scholar
  27. 27.
    Jao J, Yu W, Patel K, Miller TL, Karalius B, Geffner ME, DiMeglio LA, Mirza A, Chen JS, Silio M, McFarland EJ, Van Dyke RB, Jacobson D; Pediatric HIV/AIDS Cohort Study (PHACS) AdolescentMaster Protocol (AMP) study (2018) Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study. HIV Med 19(3):175–183.  https://doi.org/10.1111/hiv.12566 CrossRefPubMedGoogle Scholar
  28. 28.
    Briz V, Leon-Leal JA, Palladino C et al (2012) Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents. Pediatr Infect Dis J 31(3):273–277. http://www.ncbi.nlm.nih.gov/pubmed/22330165 CrossRefGoogle Scholar
  29. 29.
    Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, Mofenson L, Fiscus S, Rathore M, Jimenez E, Borkowsky W, Pitt J, Smith ME, Wells B, McIntosh K (2000) Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA 283(4):492–498CrossRefGoogle Scholar
  30. 30.
    Nachman S, Zheng N, Acosta EP, et al (2014) Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis 58(3):413–422. http://www.ncbi.nlm.nih.gov/pubmed/24145879 CrossRefGoogle Scholar
  31. 31.
    Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, Lutz T, Angel JB, Richmond GJ, Clotet B, Gutierrez F, Sloan L, Clair MS, Murray M, Ford SL, Mrus J, Patel P, Crauwels H, Griffith SK, Sutton KC, Dorey D, Smith KY, Williams PE, Spreen WR (2017) Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet 390(10101):1499–1510CrossRefGoogle Scholar
  32. 32.
  33. 33.
    Mandelbrot L, Tubiana R, Le Chenadec J, Dollfus C, Faye A, Pannier E, Matheron S, Khuong MA, Garrait V, Reliquet V, Devidas A, Berrebi A, Allisy C, Elleau C, Arvieux C, Rouzioux C, Warszawski J, Blanche S; ANRS-EPF Study Group (2015) No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin Infect Dis 61(11):1715–1725.  https://doi.org/10.1093/cid/civ578 CrossRefPubMedGoogle Scholar
  34. 34.
    Epidemiologisches Bulletin, 30.9.2005, Nr. 39, http://www.RKI.de
  35. 35.
    Niehues T (2017) Impfen bei Immundefizienz. Bundesgesundheitsblatt 60:674–684CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Uwe Wintergerst
    • 1
    Email author
  • Ulrich Baumann
    • 2
  • Ulrich v. Both
    • 3
  • Bernd Buchholz
    • 4
  • Cornelia Feiterna-Sperling
    • 5
  • Elisabeth Förster-Waldl
    • 6
  • Robin Kobbe
    • 7
  • Christoph Königs
    • 8
  • Elke Maritz
    • 9
  • Jennifer Neubert
    • 10
  • Tim Niehues
    • 11
  • Gundula Notheis
    • 12
  • Paolo Paioni
    • 13
  1. 1.Abteilung für Kinder- und JugendheilkundeKrankenhaus St. JosefBraunauÖsterreich
  2. 2.Universitäts-Kinderklinik HannoverHannoverDeutschland
  3. 3.Kinderklinik und KinderpoliklinikDr. von Haunersches KinderspitalMünchenDeutschland
  4. 4.Universitäts-Kinderklinik MannheimMannheimDeutschland
  5. 5.Charité – Universitätsmedizin BerlinBerlinDeutschland
  6. 6.Universitäts-Kinderklinik WienWienÖsterreich
  7. 7.Universitäts-Kinderklinik HamburgHamburgDeutschland
  8. 8.Universitäts-Kinderklinik FrankfurtFrankfurtDeutschland
  9. 9.Kinderarztpraxis in FreiburgFreiburgDeutschland
  10. 10.Universitäts-Kinderklinik DüsseldorfDüsseldorfDeutschland
  11. 11.Kinderklinik KrefeldKrefeldDeutschland
  12. 12.Kinderklinik AugsburgAugsburgDeutschland
  13. 13.Universitäts-Kinderspital ZürichZürichSchweiz

Personalised recommendations